Share on LinkedInShare on LinkedIn

ARTICLE · 28 NOVEMBER 2017

Greg Vogel On "Government Funding For Pharmaceutical Research And Development"

All companies have to make difficult choices prioritizing objectives.

United StatesGovernment, Public Sector

All companies have to make difficult choices prioritizing objectives. In addition to other factors, pharmaceutical companies must also consider the potential of any given clinical development plan years before success or failure can be determined. Bringing a product to market is costly, not only in terms of direct research and development costs, but also the opportunity costs of potential products that get deprioritized in a company's cost-benefit analyses. These cost-benefit analyses have real world consequences - it is not an understatement to say that in the pharmaceutical field, a company's decisions, successes, and failures directly affect the lives of its end users.

U.S. government contracts can nudge companies toward developing drugs, countermeasures, and related diagnostics deemed essential to U.S. public health and safety and can alter a company's priorities. For example, programs managed by the Department of Health and Human Services (HHS) in recent years

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from